NCT00630643View on ClinicalTrials.gov

NI-0401 in Active Crohn's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Moderate to Severe Crohn's Disease
Interventions
BIOLOGICAL

NI-0401 (anti-CD3 mAB)

0.05 mg up to 10 mg

DRUG

Placebo

Placebo

Sponsors
All Listed Sponsors
lead

Light Chain Bioscience - Novimmune SA

INDUSTRY

NCT00630643 - NI-0401 in Active Crohn's Disease | Biotech Hunter | Biotech Hunter